We're here to help during Covid-19. Find out more here.
Up to four weeks before starting study treatment, all participants will have either a CT Scan, MRI, or PET with dedicated CT Scan, provide a research tumour biopsy of the cancer (taken within one year of starting the study) and research blood tests.
There will be two cohorts of patients:
Participants will receive:
Participants will receive durvalumab and trastuzumab every three weeks for 12 doses (total 36 weeks). Tremelimumab will not be given.
Research blood samples will be taken every nine weeks, before each dose of study treatment.
Participants in the 'priming dose' cohort will receive:
Research blood samples will be taken at week 10 and week 16 of the study.
Oestrogen-receptor-positive patients will also start or continue endocrine therapy (aromatase inhibitor and/or GnRH agonist).
Participants will be clinically assessed prior to each study treatment. Two core biopsies, if feasible, will be taken from the same site as the initial biopsy about three weeks after starting study treatment.
Participants will be clinically assessed prior to each study treatment. During the study, heart function tests (ECHO or MUGA) will be performed every three months as per standard of care, or as clinically indicated.
The full length of treatment is 52 weeks (one year). After completing study treatment, patients will be followed every three months by either clinic visits or via telephone.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at firstname.lastname@example.org
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to email@example.com
Subscribe for updates & stay in the loop with new studies.